NeuroBo Pharmaceuticals has completed the last patient visit in its Phase 2a clinical trial evaluating DA-1241 for metabolic dysfunction-associated steatohepatitis (MASH).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.